Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review

Rigel Pharmaceuticals Inc (RIGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. The company’s lead product, the US FDA approved Tavalisse (fostamatinib disodium hexahydrate), is an oral spleen tyrosine kinase inhibitor to treat adult patients with chronic immune thrombocytopenia. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca, Kissei, Grifols, Merck, Novartis and Bristol-Myers Squibb. Rigel is headquartered in South San Francisco, California, the US.

Rigel Pharmaceuticals Inc Key Recent Developments

Mar 26,2019: Rigel welcomes Jane Wasman to board of directors
Feb 28,2019: Rigel reports fourth quarter and full year 2018 financial results and provides company update
Nov 06,2018: Rigel announces third quarter 2018 financial results and provides company update
Aug 08,2018: Rigel Pharmaceutical reports second quarter 2018 financial results
May 01,2018: Rigel Reports First Quarter 2018 Financial Results

Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
Rigel Pharmaceuticals Inc - Key Facts
Rigel Pharmaceuticals Inc - Key Employees
Rigel Pharmaceuticals Inc - Key Employee Biographies
Rigel Pharmaceuticals Inc - Major Products and Services
Rigel Pharmaceuticals Inc - History
Rigel Pharmaceuticals Inc - Company Statement
Rigel Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
Rigel Pharmaceuticals Inc - Business Description
Rigel Pharmaceuticals Inc - Corporate Strategy
Rigel Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Rigel Pharmaceuticals Inc - Strengths
Rigel Pharmaceuticals Inc - Weaknesses
Rigel Pharmaceuticals Inc - Opportunities
Rigel Pharmaceuticals Inc - Threats
Rigel Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Rigel Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 26, 2019: Rigel welcomes Jane Wasman to board of directors
Feb 28, 2019: Rigel reports fourth quarter and full year 2018 financial results and provides company update
Nov 06, 2018: Rigel announces third quarter 2018 financial results and provides company update
Aug 08, 2018: Rigel Pharmaceutical reports second quarter 2018 financial results
May 01, 2018: Rigel Reports First Quarter 2018 Financial Results
Mar 06, 2018: Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Rigel Pharmaceuticals Inc, Key Facts
Rigel Pharmaceuticals Inc, Key Employees
Rigel Pharmaceuticals Inc, Key Employee Biographies
Rigel Pharmaceuticals Inc, Major Products and Services
Rigel Pharmaceuticals Inc, History
Rigel Pharmaceuticals Inc, Key Competitors
Rigel Pharmaceuticals Inc, Ratios based on current share price
Rigel Pharmaceuticals Inc, Annual Ratios
Rigel Pharmaceuticals Inc, Annual Ratios (Cont...1)
Rigel Pharmaceuticals Inc, Interim Ratios
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Rigel Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


Rigel Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Rigel Pharmaceuticals Inc, Ratio Charts
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
 


Rigel Pharmaceuticals Inc (RIGL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus

USD 250 View Report

Rigel Pharmaceuticals, Inc. - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Rigel Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Rigel Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

EyePoint Pharmaceuticals Inc (PSDV) - Product Pipeline Analysis, 2019 Update

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert

USD 750 View Report

RespireRx Pharmaceuticals Inc (RSPI) - Strategic SWOT Analysis Review

RespireRx Pharmaceuticals Inc (RSPI) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis,

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available